Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06116136 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
A Phase 1 study of MSI-H/dMMR Gastric Cancer and MSI-H/dMMR Gastroesophageal-junction Cancer, sponsored by Servier Bio-Innovation.
- Active
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 20
- Study locations
NCT06116136: Active Phase 1 study of MSI-H/dMMR Gastric Cancer and MSI-H/dMMR Gastroesophageal-junction Cancer, sponsored by Servier Bio-Innovation.
NCT06116136 is a Phase 1 study of MSI-H/dMMR Gastric Cancer and MSI-H/dMMR Gastroesophageal-junction Cancer that is active but no longer recruiting, run by Servier Bio-Innovation. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06116136, a Phase 1 study of MSI-H/dMMR Gastric Cancer and MSI-H/dMMR Gastroesophageal-junction Cancer, is active but no longer recruiting, sponsored by Servier Bio-Innovation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.
Primary Outcome
Phase 1b and Phase 2
Conditions Studied
Interventions
- DRUG S095029
- DRUG pembrolizumab 200 mg (KEYTRUDA ®)
Study Locations (20)
Other
- The Queen Elizabeth Hospital - Woodville South
- Landeskrankenhaus (SALK) - Salzburg
- UZ Leuven Campus Gasthuisberg - Leuven
- Chu de Liege - Liège
- Cepon - Centro de Pesquisas Oncologicas - Florianópolis
- Supera Oncologia - Santa Catarina
- Icesp - Instituto Do Câncer Do Estado de São Paulo - São Paulo
- Instituto Brasileiro de Controle Do Câncer - São Paulo
- Hospital Albert Einstein - São Paulo
- Mount Sinai Hospital - Toronto
Florida
- Ocala Oncology Center Pl - Ocala
Indiana
- Investigative Clinical Research of Indiana, Llc - Noblesville
Texas
- MD Anderson Cancer Center - Houston
Upper Austria
- Ordensklinikum Linz - Linz
Vienna
- Med Universitat Wien-Allgemeines Krankenhaus Der Stadt Wien (AKH) - Vienna
Beijing Municipality
- Beijing Cancer Hospital - Beijing
Heilongjiang
- Harbin Medical University Cancer Hospital - Harbin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-08-31 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
What the registry record for NCT06116136 still lists
NCT06116136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 2 conditions, with MSI-H/dMMR Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which S095029 is the first listed.
NCT06116136 names 20 study sites across 11 states, led by Other, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT06116136 about?
NCT06116136 is a clinical study titled "A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.". This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.
What is the current status of trial NCT06116136?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2024-08-31. Estimated completion is 2026-08.
What conditions does trial NCT06116136 study?
This clinical trial studies the following conditions: MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT06116136?
The interventions under investigation include: S095029 (DRUG), pembrolizumab 200 mg (KEYTRUDA ®) (DRUG).
Who is sponsoring clinical trial NCT06116136?
This trial is sponsored by Servier Bio-Innovation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06116136 being conducted?
This trial has 20 study locations across Florida, Indiana, Texas, Upper Austria, Vienna. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MSI-H/dMMR Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06116136's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI